Arkolith/Insider Trading/SYRS/Form 4

Stephens Kristin

Chief Development OfficerSyros Pharmaceuticals, Inc. (SYRS) · full profile →Form 4 · filed Apr 2, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 1, 2024Tax withholding(F)4K$5.12$22K25K
Mar 31, 2024Option exercise(M)2K——18K
Mar 31, 2024Option exercise(M)12K——29K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 31, 2024Option exercise(M)2K—$04K
Mar 31, 2024Option exercise(M)12K—$023K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-040320) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML